These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36773220)

  • 1. A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America.
    Winn A; Basu A; Ramsey SD
    Pharmacoecon Open; 2023 Mar; 7(2):313-320. PubMed ID: 36773220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
    Gallagher ME; Chawla A; Brady BL; Badawy SM
    J Med Econ; 2022; 25(1):1140-1148. PubMed ID: 36222016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
    Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current modalities of sickle cell disease management.
    Sanyaolu A; Agiri E; Bertram C; Brookes L; Choudhury J; Datt D; Ibrahim A; Maciejko A; Mansfield A; Nkrumah J; Williams M
    Blood Sci; 2020 Oct; 2(4):109-116. PubMed ID: 35400022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review.
    Lee S; Vania DK; Bhor M; Revicki D; Abogunrin S; Sarri G
    Int J Gen Med; 2020; 13():361-377. PubMed ID: 32753936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease.
    Johnson KM; Jiao B; Bender MA; Ramsey SD; Devine B; Basu A
    PLoS One; 2022; 17(4):e0267448. PubMed ID: 35482721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
    Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
    Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the public health impact of voxelotor in the management of sickle cell disease in France.
    Galacteros F; Ethgen O; Beillat M
    PLoS One; 2023; 18(9):e0291211. PubMed ID: 37703228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
    Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
    JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease.
    Lubeck D; Agodoa I; Bhakta N; Danese M; Pappu K; Howard R; Gleeson M; Halperin M; Lanzkron S
    JAMA Netw Open; 2019 Nov; 2(11):e1915374. PubMed ID: 31730182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis.
    Baldwin Z; Jiao B; Basu A; Roth J; Bender MA; Elsisi Z; Johnson KM; Cousin E; Ramsey SD; Devine B
    Pharmacoecon Open; 2022 Jul; 6(4):469-481. PubMed ID: 35471578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance.
    Johnson KM; Jiao B; Ramsey SD; Bender MA; Devine B; Basu A
    Blood Adv; 2023 Feb; 7(3):365-374. PubMed ID: 35575558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of sickle cell disease in Brazil.
    Silva-Pinto AC; Costa FF; Gualandro SFM; Fonseca PBB; Grindler CM; Souza Filho HCR; Bueno CT; Cançado RD
    PLoS One; 2022; 17(6):e0269703. PubMed ID: 35709301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition for Adolescents and Young Adults With Sickle Cell Disease in a US Midwest Urban Center: A Multilevel Perspective on Barriers, Facilitators, and Future Directions.
    Calhoun C; Luo L; Baumann AA; Bauer A; Shen E; McKay V; Hooley C; James A; King AA
    J Pediatr Hematol Oncol; 2022 Jul; 44(5):e872-e880. PubMed ID: 35731941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
    Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease.
    Gondek LP; Sheehan VA; Fitzhugh CD
    J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.
    Ansari J; Moufarrej YE; Pawlinski R; Gavins FNE
    Expert Rev Hematol; 2018 Jan; 11(1):45-55. PubMed ID: 29207881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Qualitative Analysis of State Medicaid Coverage Benefits for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Sickle Cell Disease (SCD).
    Mupfudze TG; Preussler JM; Sees JA; SanCartier M; Arnold SD; Devine S
    Transplant Cell Ther; 2021 Apr; 27(4):345-351. PubMed ID: 33836889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.